Induction of IL-1 receptor antagonist by interferon beta: Implication for the treatment of multiple sclerosis

Journal of NeuroVirology

Volumn 6, Issue SUPPL. 2, 2000, Pages

  Sciacca, Francesca Luisa ^a   Canal, Nicola ^a   Grimaldi, Luipi Maria Edoardo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

IFN ; IL 1ra; Myelomonocytic cell lines

Indexed keywords

BETA INTERFERON; DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MESSENGER RNA;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES; BLOTTING, NORTHERN; GENE EXPRESSION; HUMANS; INTERFERON-BETA; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LEUKEMIA, MONOCYTIC, ACUTE; MONOCYTES; MULTIPLE SCLEROSIS; RNA, MESSENGER; SIALOGLYCOPROTEINS; U937 CELLS;

EID: 0034129854     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Abramovich C, Hulman LM, Ratovitski E, Harroch S, Tovey M, Eid P, Revel M (1994). Differential tyrosine phosphorylation in response to interferon-α and interferon-β of a surface protein associated with the IFNAR chain of the type-I interferon receptor. EMBO J 13: 5871-5877.
2. Barnes PJ (1998). Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 94: 557-572.
3. Bell JI, Lathrop GM (1996). Multiple loci for multiple sclerosis. Nat Genet 13: 377-378.
4. Cannella B, Raine CS (1995). The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 37: 424-435.
5. Dinarello CA (1996). Biological basis for interleukin-1 in disease. Blood 87: 2095-2147.
6. Eiesnberg SP, Evans RJ, Arend WP, Verderber E, Brewer MT, Hannum CH, Thompson RC (1990). Primary structure and functional expression from complementary cDNA of a human interleukin 1 receptor antagonist. Nature 343: 341-346.
7. Kline JN, Fisher PA, Monick MM, Hunninghake GW (1995). Regulation of interleukin-1 receptor antagonist by Th1 and Th2 cytokines. Am J Physiol 269: L92-L98.
8. Liu JSH, Amaral TD, Brosnan CF, Lee SC (1998). IFNs are critical regulators of IL-1 receptor antagonist and IL-1 expression in human microglia. J Immunol 161: 1989-1996.
9. Maniatis T, Fritsh EF, Sambrook J (1982). Molecular cloning: a laboratory manual. Cold Spring Harbor, New York.
10. Mannie MD, Dinarello CA, Paterson PY (1987). Interleukin-1 receptor antagonist (IL-1ra) on experimental encephalomyelitis in Lewis rats. J Immunol 138: 4229-4235.
11. Martin D, Near SL (1995). Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental encephalomyelitis in rats. J Neuroimmunol 61: 241-245.
12. Martino G, Grohovaz F, Brambilla E, Codazzi F, Filippi M, Comi G, Grimaldi LME (1998). Proinflammatory cytokines regulate antigen-independent T-cell activation by two separate calcium-signaling pathways in with multiple sclerosis patients. Ann Neurol 43: 430-439.
13. Nicoletti F, Patti F, Di Marco R, Zaccone P, Nicoletti A, Meroni P, Reggio A (1996). Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increase either during exacerbations or in response to IFN-beta treatment. Cytokine 8: 395-400.
14. Persico MG, Viglietto G, Martini G, Toniolo D, Paonessa G, Moscatelli C, Dono R, Vulliamy T, Luzzatto L, D'Urso M (1986). Isolation of human glucose-6phosphate dehydrogenase (G6PD) cDNA clones: primary structure of the protein and unusual 5′ non-coding region. Nucleic Acid Research 14: 2511-2522.
15. Traugott U (1996). Handbook of Multiple Sclerosis. In: Cook SD (ed). Marcel Dekker, New York, pp 157-185.
16. Voltz R, Hartmann M, Spuler S, Scheller A, Mai N, Hohlfeld R, Yousry T (1997). Longitudinal measurement of IL-1 receptor antagonist. J Neurol Neurosurg Psychiatry 62: 200-201.